Beyond Biotech - the podcast from Labiotech How Leyden Labs is revolutionizing flu protection with its intranasal antibody spray
Today we welcome Koenraad Wiedhaup, Co-Founder and CEO of Leyden Labs, and Clarissa Koch, the company's Chief Scientific Officer.
Leyden Labs is pioneering a revolutionary non-vaccine approach to combat respiratory viruses like influenza and coronaviruses. Recently, they published groundbreaking data in Science Translational Medicine, demonstrating that their intranasal antibody spray is safe, well-tolerated, and delivers sustained protection right at the virus's entry point: the nose. This innovation addresses the shortcomings of traditional flu vaccines, which average just 13% effectiveness against infection and provide even less for vulnerable groups like the elderly and immunocompromised.
We'll dive into the science, the company's journey since its 2020 founding, and their recent €50 million European funding boost amid U.S. biotech challenges.
01:33: Meet Koenraad Wiedhaup
03:13: Meet Clarissa Koch
04:16: Leyden Labs' origin story
06:21: Mucosal protection platform explained
08:57: Complementing existing vaccines
11:47: Science of mucosal immunity
13:24: PanFlu lead candidate overview
16:42: Key findings from recent publication
22:02: Funding and future preparedness
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic: